Pasithea Therapeutics (KTTA) Insider Trading & Ownership $0.92 -0.03 (-2.73%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.92 +0.00 (+0.40%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Pasithea Therapeutics (NASDAQ:KTTA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.30%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$787.20 Get KTTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Pasithea Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KTTA Insider Buying and Selling by Quarter Pasithea Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/12/2025Tiago MarquesCEOSell960$0.82$787.20 (Data available from 1/1/2013 forward) KTTA Insider Trading Activity - Frequently Asked Questions Who is on Pasithea Therapeutics's Insider Roster? The list of insiders at Pasithea Therapeutics includes Avi Geller, David Delaney, Eric Shahinian, Lawrence Steinman, and Tiago Marques. Learn more on insiders at KTTA. What percentage of Pasithea Therapeutics stock is owned by insiders? 16.30% of Pasithea Therapeutics stock is owned by insiders. Learn more on KTTA's insider holdings. Which Pasithea Therapeutics insiders have been buying company stock? The following insider purchased KTTA shares in the last 24 months: Lawrence Steinman ($12,900.00). How much insider buying is happening at Pasithea Therapeutics? Insiders have purchased a total of 1,500 KTTA shares in the last 24 months for a total of $12,900.00 bought. Which Pasithea Therapeutics insiders have been selling company stock? The following insider sold KTTA shares in the last 24 months: Tiago Marques ($787.20). How much insider selling is happening at Pasithea Therapeutics? Insiders have sold a total of 960 Pasithea Therapeutics shares in the last 24 months for a total of $787.20 sold. Pasithea Therapeutics Key ExecutivesDr. Lawrence Steinman BA (Age 76)M.D., Ph.D., Co-Founder, MD & Executive Chairman Compensation: $250kDr. Tiago Reis Marques M.D. (Age 46)Ph.D., CEO & Director Compensation: $480kMr. Daniel H. Schneiderman (Age 46)Chief Financial Officer Compensation: $345.94kDr. Graeme Currie Ph.D. (Age 57)Chief Development Officer Compensation: $346.62kDr. Yassine Bendiabdallah Ph.D. (Age 40)COO & Head of UK Clinics More Insider Trading Tools from MarketBeat Related Companies Cyclerion Therapeutics Insider Selling Kiora Pharmaceuticals Insider Selling Orgenesis Insider Selling Phio Pharmaceuticals Insider Selling Sensei Biotherapeutics Insider Selling Biomerica Insider Selling Creative Medical Technology Insider Selling Acurx Pharmaceuticals Insider Selling Aprea Therapeutics Insider Selling TransCode Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Turbulence for Joby Shares: What's Behind the Recent Dip?UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market Cap This page (NASDAQ:KTTA) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
